| Description | AZD-9574 is a selective inhibitor of PARP1 at the sites of SSBs. AZD-9574 exhibits anti-cancer activities and can be used in studies about HRD+ breast cancer and advanced solid malignancies. |
| In vitro | AZD-9574 inhibits PARP1 with IC50s range between 0.3-2 nM in all tested cell lines which is >8000-fold selectivity compared to PARP2, PARP3, PARP5a and PARP6[1]. |
| In vivo | In an intracranial xenograft mice model of breast cancer brain metastases, AZD-9574 (3 mg/kg) shows sustained tumour growth suppression and results in a significantly extended survival of mice[1]. |
| molecular weight | 428.44 |
| Molecular formula | C21H22F2N6O2 |
| CAS | 2756333-39-6 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: ＜1 mg/mL(insoluble or slightly soluble), Sonication and heating to 60℃ are recommended. |
| References | 1. Kunzah Jamal, et al. Abstract 2609: AZD9574 is a novel, brain penetrant PARP-1 selective inhibitor with activity in an orthotopic, intracranial xenograft model with aberrant DNA repair. Cancer Res (2022) 82 (12_Supplement): 2609. |